PL3565585T3 - Sposób leczenia przy użyciu peptydów tolerogennych - Google Patents

Sposób leczenia przy użyciu peptydów tolerogennych

Info

Publication number
PL3565585T3
PL3565585T3 PL18701797.5T PL18701797T PL3565585T3 PL 3565585 T3 PL3565585 T3 PL 3565585T3 PL 18701797 T PL18701797 T PL 18701797T PL 3565585 T3 PL3565585 T3 PL 3565585T3
Authority
PL
Poland
Prior art keywords
therapeutic method
dose escalation
escalation protocol
tolerogenic peptides
tolerogenic
Prior art date
Application number
PL18701797.5T
Other languages
English (en)
Inventor
David Wraith
Keith Martin
Original Assignee
Worg Pharmaceuticals (Zhejiang) Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Worg Pharmaceuticals (Zhejiang) Co., Ltd. filed Critical Worg Pharmaceuticals (Zhejiang) Co., Ltd.
Publication of PL3565585T3 publication Critical patent/PL3565585T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL18701797.5T 2017-01-04 2018-01-04 Sposób leczenia przy użyciu peptydów tolerogennych PL3565585T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201700111 2017-01-04
PCT/IB2018/050061 WO2018127828A1 (en) 2017-01-04 2018-01-04 Therapeutic method using tolerogenic peptides

Publications (1)

Publication Number Publication Date
PL3565585T3 true PL3565585T3 (pl) 2025-03-17

Family

ID=61054439

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18701797.5T PL3565585T3 (pl) 2017-01-04 2018-01-04 Sposób leczenia przy użyciu peptydów tolerogennych

Country Status (10)

Country Link
US (1) US20200046802A1 (pl)
EP (1) EP3565585B1 (pl)
JP (2) JP2020503353A (pl)
AU (1) AU2018206356B2 (pl)
CA (1) CA3049177A1 (pl)
ES (1) ES2996275T3 (pl)
HU (1) HUE070024T2 (pl)
PL (1) PL3565585T3 (pl)
WO (1) WO2018127828A1 (pl)
ZA (1) ZA201904384B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201919222D0 (en) * 2019-12-23 2020-02-05 Apitope Int Nv Composition
CA3182369A1 (en) 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229489B1 (hu) * 2000-08-21 2014-01-28 Apitope Technology Bristol Ltd Tolerogén peptidek
AU2006203165B2 (en) * 2000-08-21 2009-05-07 Apitope Technology (Bristol) Limited Peptide selection method
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
CA2703170C (en) * 2007-10-31 2016-10-11 Apitope Technology (Bristol) Limited Composition comprising myelin basic proteins
GB0721430D0 (en) * 2007-10-31 2007-12-12 Apitope Technology Bristol Ltd Composition
GB201314052D0 (en) * 2013-08-06 2013-09-18 Apitope Int Nv Peptides
AU2015370415B2 (en) * 2014-12-24 2022-06-02 Worg Pharmaceuticals (Zhejiang) Co., Ltd. Composition

Also Published As

Publication number Publication date
JP2023018042A (ja) 2023-02-07
JP7591017B2 (ja) 2024-11-27
AU2018206356A1 (en) 2019-07-18
ES2996275T3 (en) 2025-02-12
CA3049177A1 (en) 2018-07-12
WO2018127828A1 (en) 2018-07-12
US20200046802A1 (en) 2020-02-13
EP3565585A1 (en) 2019-11-13
HUE070024T2 (hu) 2025-05-28
JP2020503353A (ja) 2020-01-30
AU2018206356B2 (en) 2025-02-27
ZA201904384B (en) 2023-12-20
EP3565585C0 (en) 2024-11-13
EP3565585B1 (en) 2024-11-13

Similar Documents

Publication Publication Date Title
ZA201803984B (en) Pharmaceutical package for ophthalmic formulations
ZA201906613B (en) Pharmaceutical compositions for combination therapy
IL258464A (en) Pharmaceutical compositions for oral administration of peptide drugs
IL251462A0 (en) Pharmaceutical formulations for oral administration of peptide or protein drugs
EP3367979A4 (en) Implant delivery capsule
IL265463A (en) Therapeutic peptides related to mots-c
ZA201905510B (en) Pharmaceutical compositions for combination therapy
EP3220953A4 (en) COMPOSITIONS AND METHODS OF USING THERAPEUTIC p53 PEPTIDES AND ANALOGUES
EP4125973A4 (en) NEOANTIGEN VACCINE THERAPY
IL282538A (en) Methods for manufacturing therapeutic delivery platforms
HUP1700253A1 (hu) Szilárd orális gyógyszerkészítmények
EP3283095A4 (en) Therapeutic peptides for cerebrovascular diseases
IL290520A (en) Medicinal peptides
SG11201709260TA (en) Therapeutic agent for fibrosis
IL285144A (en) Medicinal peptides
IL292502A (en) Therapeutic methods using vadadustat
PL3694585T3 (pl) Urządzenie do podawania leku
IL272271A (en) A therapeutic agent for fibrosis
HUE070024T2 (hu) Dóziseszkalációs protokollt alkalmazó terápiás eljárás tolerogén peptideknél
IL283273A (en) Pharmacy practices
IL271908A (en) Over-compressed pharmaceutical preparations
GB201507760D0 (en) Gelated microparticle suitable for oral delivery of therapeutic peptides to the lower intestine
SG11202010792TA (en) Improved pharmaceutical formulations
GB201710280D0 (en) Drug delivery apparatus
IL268046B1 (en) Therapeutic peptides